fashion -WSS

fashion

author：explore 2025-08-24 05:25:45 - browse：5

Eli Lilly headquarters — Kristoffer Tripplaar/AP

SAN DIEGO – An experimental pill from Eli Lilly led to 14.7% weight loss on the highest dose in a 36-week trial, heating up the growing competition among drugmakers to develop an effective oral obesity therapy.

The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year. The full results, published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference.

By the end of trial, the authors said, participants’ weight loss had not plateaued, suggesting potential for even greater weight loss over a longer treatment period.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Why medical students are struggling with mental health

hotspot

explore

WSS

Ransomware attacks on hospitals: Study outlines patient impact

A daunting task: navigating dual Medicare, Medicaid eligibility

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

In key trial, Verve's treatment lowers cholesterol levels in patients

Hormonal contraceptives don’t actually treat endometriosis

After a decade, new Gardasil ad campaign gets it (mostly) right

explore

fashion

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Sanders wants to replace patents with prizes for drug inventions

Malaria cases in Florida and Texas: Here’s what you need to know

The stock market has soared this year, but will it last? Experts weigh in

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Drug repurposing or repositioning? The language matters

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Peter Hotez and the public health issue of online harassment

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Wikipedia

Why medical students are struggling with mental health

Wegovy, Zepbound and weight loss drugs that preserve muscle

Why medical students are struggling with mental health

US jobless claims fall again as labor market continues to flash strength

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

How a Boston hospital is priming medical residents to use GPT

hotspot

hotspot

explore

explore